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Xpert MTB/RIF Ultra for the diagnosis of HIV-associated 
tuberculous meningitis: a prospective validation study
Fiona V Cresswell, Lillian Tugume, Nathan C Bahr, Richard Kwizera, Ananta S Bangdiwala, Abdu K Musubire, Morris Rutakingirwa, Enock Kagimu, 
Edwin Nuwagira, Edward Mpoza, Joshua Rhein, Darlisha A Williams, Conrad Muzoora, Daniel Grint, Alison M Elliott, David B Meya, 
David R Boulware, on behalf of the ASTRO-CM team
Summary
Introduction Tuberculous meningitis accounts for 1–5% of tuberculosis cases. Diagnostic delay contributes to poor 
outcomes. We evaluated the performance of the new Xpert MTB/RIF Ultra (Xpert Ultra) for tuberculous meningitis 
diagnosis.
Methods In this prospective validation study, we tested the cerebrospinal fluid (CSF) of adults presenting with 
suspected meningitis (ie, headache or altered mental status with clinical signs of meningism) to the Mulago National 
Referral Hospital and Mbarara Regional Referral Hospital in Uganda. We centrifuged the CSF, resuspended the cell 
pellet in 2 mL CSF, and tested 0·5 mL aliquots with Xpert Ultra, Xpert MTB/RIF (Xpert), and mycobacterial growth 
indicator tube (MGIT) culture. We quantified diagnostic performance against the uniform case definition of probable 
or definite tuberculous meningitis and a composite microbiological reference standard.
Findings From Nov 25, 2016, to Jan 24, 2019, we screened 466 adults with suspected meningitis and tested 204 for 
tuberculous meningitis. Uniform clinical case definition classified 51 participants as having probable or definite 
tuberculous meningitis. Against this uniform case definition, Xpert Ultra had 76·5% sensitivity (95% CI 62·5–87·2; 
39 of 51 patients) and a negative predictive value of 92·7% (87·6–96·2; 153 of 165), compared with 55·6% sensitivity 
(44·0–70·4; 25 of 45; p=0·0010) and a negative predictive value of 85·8% (78·9–91·1; 121 of 141) for Xpert and 
61·4% sensitivity (45·5–75·6; 27 of 44; p=0·020) and negative predictive value of 85·2% (77·4–91·1; 98 of 115) 
for MGIT culture. Against the composite microbiological reference standard, Xpert Ultra had sensitivity of 
92·9% (80·5–98·5; 39 of 42), higher than Xpert at 65·8% (48·6–80·4; 25 of 38; p=0·0063) and MGIT culture at 
72·2% (55·9–86·2; 27 of 37; p=0·092). Xpert Ultra detected nine tuberculous meningitis cases missed by Xpert and 
MGIT culture.
Interpretation Xpert Ultra detected tuberculous meningitis with higher sensitivity than Xpert and MGIT culture in 
this HIV-positive population. However, with a negative predictive value of 93%, Xpert Ultra cannot be used as a rule-
out test. Clinical judgment and novel highly sensitive point-of-care tests are still required.
Funding Wellcome Trust, National Institute of Health, National Institute of Neurologic Diseases and Stroke, 
Fogarty International Center, and National Institute of Allergy and Infectious Diseases.
Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Worldwide, Mycobacterium tuberculosis affected more than 
10 million people in 2018, with devastating con sequences, 
including around 1·5 million deaths.1 Tuberculous 
meningitis, the most serious form of tuberculosis in­
fection, accounts for 1–5% of new cases of tuberculosis 
and results in death or substantial disability in more than 
half of those affected.2 Outcomes are particularly poor 
in patients with HIV co­infection, which can triple the 
risk of death from tuberculous meningitis, reaching 
approximately 50%.3 Another major driver of poor out­
comes is diagnostic delay.4
Cerebrospinal fluid (CSF) smear microscopy with 
Ziehl–Neelsen staining for acid­fast bacilli is the 
cheapest and most widely available test for tuberculous 
meningitis diagnosis, but it is insensitive in most 
settings with out expert microscopists.5–7 Culture takes a 
minimum of 2 weeks to provide results (too slow for 
clinical utility), has only moderate sensitivity (30–60%), 
and is not readily available in most settings within 
low­income tuberculosis­endemic countries.8,6 Xpert 
MTB/RIF (Xpert; Cepheid, Sunnyvale, CA, USA)—a 
rapid, automated, cartridge­based mol ecular test—was 
endorsed by WHO in 2015 as the best initial test for 
tuberculous meningitis.9 Xpert has been deployed in 
130 of 145 countries eligible for concessional pricing 
as of 2016.10 Xpert provides 45–67% sensitivity to 
detect microbiologically proven tuberculous meningitis, 
meaning a negative result does not provide adequate 
confidence that tuberculous menin gitis is not present.8,11 
Thus, empirical antituberculous therapy for tuberculous 
meningitis, with its associated drug toxicities, drug–
drug interactions, pill burden, and cost, is still commonly 
used, often unnecessarily.
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Subsequently, Xpert MTB/RIF Ultra (Xpert Ultra) was 
developed, which has a larger chamber (50 µL) for DNA 
amplification than Xpert, allowing twice the volume of 
sample to reach the PCR reaction. Xpert Ultra also has 
two new multicopy DNA targets (IS6110 and IS1081), 
incorporates fully nested nucleic acid amplification, 
and uses melting temperature­based analysis instead of 
real­time PCR to improve the accuracy of rifampicin­
resistance detection. In vitro, these changes have made 
the limit of detection of M tuberculosis seven times 
lower (16 vs 113 colony forming units [CFUs] per mL).12,13 
Another important benefit of Xpert Ultra is the 
shortened run time of 84 min (compared with 112 min 
for Xpert), enabling an extra five tests to be run on each 
module in a working day, equating to an extra 40 tests 
per day on an eight­module unit. To upgrade from Xpert, 
only new software and the Xpert Ultra cartridges are 
required—the same instrument can be used. Previous 
studies have shown that Xpert Ultra’s sensitivity is 
markedly improved over Xpert’s in smear­negative 
pulmonary tuberculosis (63% vs 46%),14 HIV­associated 
pulmonary tuberculosis (90% vs 77%),14 and paediatric 
tuberculosis (74% vs 63%).15 The largest study to 
date of Xpert Ultra in tuberculous meningitis used 
cryopreserved CSF samples and found sensitivities of 
95% (95% CI 77–99) for Xpert Ultra and the same 
sensitivity of 45% (24–68) for each of Xpert and 
mycobacterial growth indicator tube (MGIT) culture 
against a composite microbiological reference standard.8 
Against the uniform clinical case definition of probable 
or definite tuberculous meningitis,16 sensitivity was 
70% (47–87; 16 of 23 patients) for Xpert Ultra and 
43% (23–66; ten of 23) for both culture and Xpert.8 Four 
additional small studies on CSF (containing a minimum 
of four and a maximum of 43 samples) corroborated the 
increased sensitivity of Xpert Ultra.17–20 Additional larger 
studies using real­time CSF samples and prespecified 
reference standards are needed to better inform the 
current understanding of Xpert Ultra’s performance in 
tuberculous meningitis.
The aim of this study was to prospectively assess 
the diagnostic accuracy of Xpert Ultra for tuberculous 
Research in context
Evidence before this study
We searched PubMed Central for reports of Xpert MTB/RIF Ultra 
(Xpert Ultra) for the diagnosis of tuberculosis using the terms 
(“Xpert MTB/RIF Ultra” or “Xpert Ultra”) and (“tuberculosis” or 
“TB” or “tuberculous meningitis” or “TBM” or “extrapulmonary”). 
The search was done on Feb 14, 2019, with no search date or 
language restrictions.
In-vitro studies of Xpert MTB/RIF (Xpert) and Xpert Ultra assays 
have been done on sputum samples spiked with decreasing 
numbers of Mycobacterium tuberculosis H37Rv colony-forming 
units (CFUs), which found the limit of detection to be 16 CFUs 
per mL for Xpert Ultra versus 113 CFUs per mL for Xpert—a 
seven-times reduction in the limit of detection. 
This improvement signified a promising step for the diagnosis 
of paucibacillary tuberculosis. Since then, several prospective 
and retrospective studies have evaluated Xpert Ultra in 
diagnosis of adult pulmonary tuberculosis (four), paediatric 
tuberculosis (two), extrapulmonary tuberculosis (two), 
paucibacillary tuberculosis (one), and tuberculous 
meningitis (one), all of which have found Xpert Ultra to be more 
sensitive than Xpert. The largest prospective diagnostic accuracy 
study to date, including 1753 participants with suspected 
pulmonary tuberculosis, found Xpert Ultra to have superior 
sensitivity to Xpert in smear-negative pulmonary tuberculosis 
(63% vs 46%) and in HIV-associated pulmonary tuberculosis 
(90% vs 77%), albeit with a more modest difference 
of 5·4 percentage points in the general pulmonary tuberculosis 
population. To date, only Bahr and colleagues have specifically 
focused on tuberculous meningitis, testing 129 cryopreserved 
CSF samples from HIV-positive Ugandan adults and 
finding sensitivities of 70% (16 of 23 patients) for Xpert Ultra 
and 43% (ten of 23) for Xpert against a uniform reference 
standard of probable or definite tuberculous meningitis. 
The sensitivity against a composite microbiological reference 
standard was 95% (21 of 22) for Xpert Ultra and 45% (ten of 22) 
for Xpert (p=0·0010).
Added value of this study
To our knowledge, this prospective study is the largest to date 
to investigate the diagnostic performance of Xpert Ultra for 
tuberculous meningitis. It corroborates the findings from 
cryopreserved CSF samples and adds to the data on use of Xpert 
Ultra in HIV-positive populations and in paucibacillary forms of 
tuberculosis. We tested each sample with Xpert and Xpert Ultra 
to allow direct head-to-head comparisons of the performance 
of the two assays. To optimise the uniform case definition 
reference standard, we endeavoured to exclude other 
non-tuberculosis causes of meningitis by testing CSF with 
a meningoencephalitis PCR panel (testing for 14 viral, 
bacterial, and fungal pathogens) and offering post-mortem 
examinations when possible for participants who died without 
a microbiologically confirmed diagnosis.
Implications of all the available evidence
Our results support the WHO recommendations to use Xpert 
Ultra as the initial test for suspected tuberculous meningitis. 
With its run-time of 84 min, Xpert Ultra, in the context of 
appropriate infrastructure, holds potential to provide same-day 
results and facilitate prompt tuberculous meningitis treatment. 
Nonetheless, Xpert Ultra’s imperfect negative predictive value 
(92·7% [95% CI 87·6–96·2] vs the uniform clinical case 
definition in this study) means that clinical judgment must 
override a negative Xpert Ultra result and empirical tuberculosis 
treatment is still warranted in cases where there is a high index 
of suspicion.
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meningitis compared with Xpert using fresh CSF 
specimens from an HIV­positive population.
Methods
Study design and population
In this diagnostic accuracy study, we prospectively eval­
uated adults (aged ≥18 years) presenting consecutively to 
Mulago National Referral Hospital, Kampala, and Mbarara 
Regional Referral Hospital, Mbarara, Uganda, with 
suspected meningitis (headache for >3 days or altered 
mental status [Glasgow Coma Scale <15] with clinical signs 
of meningism at examination—ie, neck stiffness or 
Kernig’s sign). The period of enrolment ran from 
Nov 26, 2016, to Jan 24, 2019, at Mulago National Referral 
Hospital and from Nov 25, 2016, to June 13, 2017, at 
Mbarara Regional Referral Hospital. Ethical approval was 
obtained from the Mulago Hospital, London School of 
Hygiene & Tropical Medicine, and University of Minnesota 
institutional review boards and Uganda National Council 
of Science and Technology, and informed consent was 
obtained from participants or their surrogate (in patients 
with altered mental status) as part of the screening process 
for a meningitis clinical trial (NCT01802385) that 
subsequently rolled into an observational diagnostic study. 
The study was conducted in line with the Standards for 
Reporting Diagnostic Accuracy Studies.21
Procedures
Given the high prevalence of cryptococcus and the similar 
initial presentations between cryptococcal meningitis and 
tuberculous meningitis, fingerstick cryptococcal antigen 
lateral flow assay (LFA; Immy, Norman, OK, USA) was 
done at the participant’s bedside. Thereafter, lumbar 
puncture was done for all participants, CSF opening 
pressure was recorded, and CSF was collected into a 
sterile tube with a target volume of more than 6 mL. At 
the bedside, CSF glucose and lactate were measured from 
a drop of CSF collected into an Eppendorf tube using a 
handheld OneTouch glucose meter (OneTouch; Lifescan, 
Inverness, UK) and a point­of­care lactate meter (Nova 
Biomedical; Waltham, MA, USA). Xpert and Xpert Ultra 
results were returned to the study team within 24 h to 
guide treatment decisions.
Clinical history, physical examination, and detailed 
neurological assessment findings were recorded as rec­
ommended by the Tuberculous Meningitis International 
Research Consortium.22 Other diagnostic tests, including 
urine tuberculosis lipoarabinomannan (Alere Determine; 
Alere, Waltham, MA, USA), chest radiograph, abdominal 
ultrasonography, brain imaging, and sputum Xpert, were 
done as clinically indicated and when locally available.
Microbiological testing
Laboratory CSF testing included white blood cell count, 
lymphocyte percentage, differential Gram stain, aerobic 
bacterial culture, Ziehl–Neelsen acid­fast bacilli stain 
(Kampala only), total protein, CSF cryptococcal anti gen, 
and Biofire FilmArray menin goencephalitis PCR panel 
(bioMérieux; Durham, NC, USA) for 14 meningo­
encephalitis pathogens (Streptococcus pneu moniae, Neisseria 
meningitidis, Listeria monocytogenes, Haemophilus influenzae, 
Strepto coccus agalactiae, Esche richia coli, herpes simplex 
virus types 1 and 2, cyto megalovirus, varicella zoster virus, 
human herpes virus 6, enterovirus, human parechovirus, 
and cryptococcus). All samples that were negative for 
CSF cryptococcal antigen underwent com prehensive 
tuber culosis diagnostic studies. Samples positive for 
cryptococcal antigen under went fungal culture and, in the 
event of fungal growth, quantitative fungal culture count.
For tuberculosis analysis, the CSF was centrifuged at 
3000 g for 20 min to concentrate bacilli into the cell pellet. 
Supernatant was pipetted out to leave a residual volume of 
2 mL in which the cell pellet was re­suspended by 
vortexing. The resuspended cell pellet was then divided 
into four 0·5 mL aliquots for Xpert, Xpert Ultra, MGIT 
culture, and cryopreservation at −80°C in case of invalid 
results from Xpert or Xpert Ultra or for future sequencing 
work. The aliquots for Xpert and Xpert Ultra were mixed 
with 1·5 mL of sample reagent, shaken vigorously, allowed 
to sit for 15 min, and then run on the Cepheid platform. 
The 0·5 mL aliquot for MGIT culture was added to the 
MGIT tube and incubated in a Bactec 960 instrument 
(Becton Dickinson; Franklin Lakes, NJ, USA). The 
algorithm for CSF diagnostic testing is illustrated in the 
appendix (p 2). Where the volume of CSF was below 6 mL, 
a stepwise approach was used to maximise the likelihood 
of yielding a diagnosis for the participant, as shown in the 
appendix (p 4). At the clinician’s discretion, participants 
with a positive test for CSF cryptococcal antigen were 
allowed to undergo tuber culous meningitis testing as 
cryptococcosis coinfection with tuberculous meningitis 
does occur, although rarely.23 In Mbarara, tuberculosis 
testing was done at the Médecins Sans Frontières 
Epicentre laboratory. In Kampala, testing was done at the 
Makerere University Micro biology Laboratory, Makerere 
University Mycobacteriology (BSL­3) laboratory (MGIT 
culture), and the Infectious Diseases Institute Trans­
lational laboratory (Xpert and Xpert Ultra). Clinical 
information was not available to the performers of the 
index or reference tests. The same laboratory technologist 
performed Xpert and Xpert Ultra, but MGIT results were 
read and reported by a different technologist.
Xpert results are reported as follows: M tuberculosis not 
detected; invalid, if the internal quality control checks 
fail; or, if M tuberculosis DNA is detected, a semi­
quantitative category of very low, low, medium, or high 
is given. Xpert Ultra results are reported in the same way 
but with the addition of the trace semi­quantitative 
category for the lowest bacillary loads (less than 
approximately 113 CFUs per mL). Rifampicin resistance 
is reported as indeterminate for tests positive in the 
trace category as the DNA quantity is too low to 
adequately detect rifampicin resistance conferring 
mutations.
See Online for appendix
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For participants who died during hospitalisation at 
Mulago hospital and did not have a microbiologically 
confirmed diagnosis, the families were invited to provide 
informed consent for post­mortem examination in the 
Makerere University mortuary by a trained pathologist. 
Post­mortem examinations were unavailable in Mbarara. 
Additionally, CSF samples collected from participants 
with cryptococcal meningitis and who survived without 
tuberculosis therapy (ie, negative controls) were run on 
Xpert Ultra from the same parent study (NCT01802385).
Statistical analysis
We assessed the diagnostic accuracy of Xpert Ultra against 
two reference standards. For the primary reference 
standard, we used the consensus uniform case definition 
of probable (≥10 points on the diagnostic scoring system 
when brain imaging is not available or ≥12 points when 
brain imaging is available) or definite (microbiologically 
confirmed M tuberculosis) tuberculous meningitis.16 We 
also used a composite microbiological reference standard 
of any positive CSF test (Ziehl–Neelsen stain microscopy, 
Xpert, Xpert Ultra, and MGIT) for M tuberculosis. Here, 
we included the index test (Xpert Ultra) in the reference 
standard as the existing tests are imperfect, and we judged 
the likelihood of false­positive detection of M tuberculosis 
DNA in the CSF of an HIV­positive person with aseptic 
meningitis in a tuberculosis­endemic area to be extremely 
low.
Baseline clinical characteristics were compared between 
those with definite tuberculous meningitis and the re­
maining participants, who were classified as other menin­
gitis, via Wilcoxon rank­sum test for continuous variables 
and Pearson’s χ² squared or Fisher’s exact test for 
categorical variables. We directly compared the sensitivity 
of Xpert Ultra with that of Xpert or MGIT using McNemar’s 
test for paired categorical data. For the comparison of two 
diagnostic test performances against the primary reference 
standard, we used the Cochran–Mantel–Haenszel statistic 
for comparing matched catego rical data across two strata 
of diagnostic tests versus the uniform case definition.16 
Negative predictive value was calculated against the 
primary reference standard, both with and without the 
Figure 1: Flow diagram showing the diagnostic outcomes of the study population
Xpert=Xpert MTB/RIF. MGIT=mycobacterial growth indicator tube. HSV=herpes simplex virus. CSF=cerebrospinal fluid. *Five participants with confirmed tuberculous 
meningitis had a positive CSF cryptococcal antigen test, of whom two had culture-confirmed cryptococcal meningitis. †Culture or PCR positive. ‡Two HSV type 1, 
two HSV type 2, two varicella zoster virus, and one cytomegalovirus. §One confirmed Streptococcus pneumoniae on PCR, four clinical diagnosis of bacterial meningitis 
based on CSF picture (ie, high CSF white blood cell count with neutrophil predominance suggestive of bacterial meningitis).
466 participants screened
262 with cryptococcal meningitis
 and no suspicion of disseminated
 tuberculosis 
204 tested with Xpert Ultra
39 positive for tuberculous meningitis by Xpert Ultra165 negative for tuberculous meningitis by Xpert Ultra
162 negative by Xpert and MGIT culture 3 positive by Xpert or MGIT culture
 2 MGIT culture only
 1 MGIT culture and Xpert
9 negative by Xpert and MGIT culture 30 positive by Xpert or MGIT culture
18 MGIT culture and Xpert
6 MGIT culture only
6 Xpert only
204 with final diagnosis
42 with tuberculous meningitis*
3 negative by Xpert Ultra
39 positive by Xpert Ultra
162 without tuberculous meningitis
112 unknown 
34 cryptococcal meningitis†
7 viral meningitis‡
5 bacterial meningitis§
2 cerebral vascular accident
1 progressive multifocal
   leukoencephalopathy
1 benign intracranial hypertension
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Xpert Ultra result being used to assign the uniform case 
definition category. Calculation of specificity and positive 
predictive value was done against the composite endpoint 
and the uniform case definition using 2 × 2 tables. We 
counted invalid tests (eg, culture contamination or Xpert 
error) as negative results. Additionally, a sensitivity analysis 
was done including only participants who received all 
three tests. We did univariate and multivariable logistic 
regression analysis to identify variables that correlate with 
microbiological confirmation of tuberculous meningitis. 
Variables which showed association in the univariate 
analysis (likelihood ratio test p<0·1) were eligible to be 
included in the multivariable model. Variables that were 
not normally distributed were log transformed.
Sample size calculation was done using the composite 
microbiological refe rence standard. For the paired analysis 
comparing the sensitivity of Xpert Ultra with that of Xpert 
or MGIT among participants positive for tuberculous 
meningitis, we assumed a third of pairs would give 
discordant results and that the sensitivity of Xpert Ultra 
would be 25% higher than that of Xpert and MGIT.8 
Under these assumptions, we required 39 tuberculous 
meningitis cases to give 80% power with α set to 5%. 
Assuming the prevalence of tuberculous meningitis 
would be 20%, we aimed to recruit 200 participants.
We did a post­hoc analysis of the sensitivity of all assays 
according to the British Medical Research Council (MRC) 
tuberculous meningitis grade of disease severity grade 
against both reference standards (appendix p 12).
Stata version 13.1 was used for statistical analyses.
Role of the funding source
The funders had no role in study design, data collection, 
data analysis, data interpretation, or writing of the report. 
The corresponding author had full access to all the data 
in the study and had final responsibility for the decision 
to submit for publication.
Results
During the study period, 466 HIV­positive adults pre­
sented with suspected meningitis and consented to 
diagnostic lumbar puncture. Of these, 262 participants 
were diagnosed with cryptococcal meningitis and had no 
suspicion for disseminated tuberculosis warranting CSF 
tuberculosis diagnostics, so were excluded from this 
study. 204 were tested for tuberculous meningitis with 
Xpert Ultra (figure 1), of whom 195 (96%) were HIV 
positive with a median CD4 T cell count of 46 cells/μL 
(IQR 11–130). This number included 39 (19%) patients 
who had a positive CSF cryptococcal antigen test but 
were still tested for tuberculous meningitis because of 
suspected tuberculosis coinfection, and an additional 
31 (15%) of those tested for tuberculous meningitis tested 
positive for cryptococcal antigen in serum but negative in 
CSF. Biofire meningoencephalitis PCR was done on 
80 CSF samples; not all samples were tested owing to a 
technical issue with the machine. We collected a median 
of 11 mL (IQR 7–15) of CSF per participant, which left a 
median of 8 mL (5–11) of CSF to be spun down 
for tuberculosis testing after routine microbiology and 
chemistry testing had been done. Collected CSF was 
clear in 186 (91%) participants, with the remaining 
18 (9%) having turbid CSF. Brain imaging was rarely 
done (ie, in 18 participants) because of a lack of 
functioning CT scanners in the study sites. No adverse 
events were attributable to the diagnostic testing (data 
not shown).
At baseline, lack of white blood cell pleocytosis and 
con centrations of glucose, protein, and lactate differed 
significantly between those with and without micro­
biologically confirmed tuberculous meningitis (table 1). 
The demographic, clinical, and diagnostic details of 
the 42 participants with micro biologically confirmed tuber­
culous meningitis are shown in the appendix (pp 5–6).
Of the 204 participants who underwent tuberculous 
meningitis diagnostic testing, Xpert Ultra was positive in 
39, of whom Xpert was also positive in 24 and MGIT 
culture in 24 (figure 1). Xpert Ultra was negative in 
165 participants, of whom 162 were negative and three 
were positive by the composite microbiological reference 
standard (figure 1). Xpert Ultra detected nine cases of 
Definite tuberculous 
meningitis (n=42)
Other meningitis 
(n=162)
p value
Age, years 32 (29–38) 35 (28–42) 0·43
Sex ·· ·· 0·73
Female 19 (45%) 68 (42%) ··
Male 23 (55%) 94 (58%) ··
HIV status ·· ·· ··
Positive 41 (98%) 154 (95%) 0·47
Negative 1 (2%) 6 (4%) ··
Unknown 0 2 (1%) ··
On antiretroviral therapy 23 (55%) 99 (62%) 0·48
Headache duration, days 14 (7–21) 14 (5–21) 0·40
Glasgow Coma Scale 13 (10–14) 14 (13–15) 0·0012
CD4 count, cells per μL* 57 (13–108) 46 (10–188) 0·83
CSF opening pressure, cmH2O 20 (10–32) 18 (13–26) 0·91
Acellular CSF <5 cells per μL 11 (26%) 99 (61%) <0·0001
CSF white blood cells per μL† 170 (70–283) 100 (40–275) 0·085
CSF lymphocytes 100% (84–100) 100% (80–100) 0·61
CSF total protein, g/L 1·2 (0·9–2·0) 0·3 (0·2–0·8) <0·0001
CSF glucose, mmol/L 1·2 (0·9–2·0) 2·9 (1·9–4·4) <0·0001
CSF lactate, mmol/mL‡ 9·5 (4·6–11) 3·6 (2·4–5·1) <0·0001
Alive at hospital discharge 25 (60%) 101/143 (71%)§ 0·18
Values are n (%), n/N (%), or median (IQR), unless otherwise stated. p values are from Wilcoxon rank-sum for 
continuous data and Fisher’s exact test for categorical data. Patients with definite tuberculous meningitis were positive 
for tuberculous meningitis by the composite microbiological reference standard. Patients with other meningitis were 
the remaining participants, including 112 with unknown causes and 50 with known causes of meningitis (see figure 1). 
*63 participants had CD4 count data (12 in the definite tuberculous meningitis group and 51 in the other meningitis 
group). †Median values in participants with more than five white blood cells per μL of CSF. ‡Lactate concentrations 
were available for 18 participants in the tuberculous meningitis definite group and 70 in the other meningitis group. 
§19 participants had unknown status at discharge in the other meningitis group.
Table 1: Baseline characteristics of participants who underwent tuberculous meningitis testing
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tuberculous meningitis that were not identified by Xpert 
or MGIT culture (figure 2). We diagnosed probable 
or definite tuberculous meningitis in 51 (25%) of 
204 participants when including the Xpert Ultra result in 
assigning the uniform case definition. When the Xpert 
Ultra result was excluded, 44 (22%) participants were 
classified as having probable or definite tuberculous 
meningitis. Of the 42 participants with definite tuber­
culous meningitis, five (12%) tested positive for 
cryptococcal antigen in CSF, including two (5%) who had 
positive fungal cultures (quantitative cryptococcal culture 
520 000 and 20 000 CFUs per mL; figure 1).
We identified alternative causes of meningitis in 
49 (30%) of the 162 participants without confirmed 
tuberculous meningitis (figure 1). In four patients without 
confirmed tuberculous meningitis who died in hospital, 
post­mortem examinations were done and causes of 
death were herpes simplex virus meningoencephalitis, 
pro gressive multifocal leukoencephalopathy, and dissemi­
nated tuberculosis without obvious CNS involvement in 
one patient; progressive multifocal leukoencephalopathy 
(PML) in one patient; pneumonia with no obvious CNS 
pathology in one patient; and meningoencephalitis with 
macroscopic appearance that was compatible with tuber­
culous meningitis, with histopathological confirmation 
awaited, in one patient.
Among the 42 participants with definite tuberculous 
meningitis, 17 (40%) died in hospital, with a median time 
to death of 4 days (IQR 2–6). Among the 162 patients in 
the other meningitis group, hospital outcome was known 
for 143, of whom 19 (13%) died in hospital.
When compared with the uniform case definition 
(probable or definite tuberculous meningitis), sensitivities 
were 76·5% (95% CI 62·5–87·2) for Xpert Ultra, 
55·6% (44·0–70·4) for Xpert, and 61·4% (45·5–75·6) for 
MGIT (table 2). Against the composite microbiological 
reference standard, sensitivities were 92·9% (80·5–98·5) 
for Xpert Ultra, 65·8% (48·6–80·4) for Xpert, and 72·2% 
(55·9–86·2) for MGIT culture (table 2). Xpert Ultra was 
superior to Xpert in detecting tuberculous meningitis 
when either the composite micro biological reference 
standard or uniform case definition was used (table 2). 
Xpert Ultra was significantly more sensitive than MGIT 
culture when the uniform case definition was used but 
not when the composite micro biological reference 
standard was used (table 2). The negative predictive value 
of Xpert Ultra was 92·7% (87·6–96·2) against the 
uniform case definition (table 2). When including only 
the 117 participants who had received all three tests, no 
major difference in performance of any of the tests was 
observed (appendix p 7).
Of the 39 positive Xpert Ultra results, 14 were categorised 
as trace, ten as very low, seven as low, five as medium, and 
none as high; three results were unknown. Of the 14 Xpert 
Ultra trace samples, only four were positive on Xpert 
(three very low and one low) and six were positive on 
culture. Median time to CSF culture positivity was 14 days 
Figure 2: Venn diagram of positive diagnostic tests in the composite 
microbiological reference standard
The Venn diagram displays 42 participants with microbiologically confirmed 
tuberculous meningitis by either Xpert, Xpert Ultra, or MGIT culture. 
Xpert=Xpert MTB/RIF. MGIT=mycobacterial growth indicator tube.
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reference standard*
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uniform case 
definition
p value‡ Negative predictive 
value vs uniform case 
definition
Specificity vs uniform 
case definition
Xpert Ultra 204 92·9% (80·5–98·5); 
39/42
·· 76·5% (62·5–87·2); 
39/51
·· 92·7% (87·6–96·2); 
153/165
100% (97·6–100); 
153/153
Xpert 166 65·8% (48·6–80·4); 
25/38
0·0063 55·6% (44·0–70·4); 
25/45
0·0010 85·8% (78·9–91·1); 
121/141
100% (97·0–100); 
121/121
MGIT culture 142 72·2% (55·9–86·2); 
27/37
0·092 61·4% (45·5–75·6); 
27/44
0·020 85·2% (77·4–91·1); 
98/115
100% (96·3–100); 
98/98
Values are percentage (95% CI); numerator/denominator unless stated otherwise. Xpert=Xpert MTB/RIF. MGIT=mycobacterial growth indicator tube. *The composite 
microbiological reference standard included a positive CSF test on any of Ziehl–Neelsen stain microscopy, Xpert, Xpert Ultra, and MGIT culture. Specificity (and the positive 
predictive value) versus the composite endpoint is by definition 100% as the index test is included in the reference standard of definite tuberculous meningitis. If the Xpert 
Ultra result is excluded when assigning the case definition, the specificity of Xpert Ultra is 96% (95% CI 91–98; 153 of 160 patients) and the positive predictive value is 82% 
(66–93; 32 of 39). †McNemar’s test comparing the sensitivity of Xpert or MGIT culture with that of Xpert Ultra. ‡Cochran–Mantel–Haenszel test comparing the distribution of 
Xpert or MGIT results with that of Xpert Ultra results against the uniform clinical standard of definite or probable tuberculous meningitis.
Table 2: Diagnostic performance of Xpert, Xpert Ultra, and MGIT culture for the diagnosis of tuberculous meningitis
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(IQR 10–15). Median time to positivity by Xpert Ultra semi­
quantitative category was 15 days (13–15) for trace, 15 days 
(12–15) for very low, 12 days (9–21) for low, and 9 days (8–9) 
for medium (appendix pp 3, 8).
No cases of rifampicin resistance were identified with 
either Xpert or Xpert Ultra. Positive samples classed in the 
Xpert Ultra trace category have in determinate rifampicin 
resistance because more than 16 CFUs per mL of 
M tuberculosis and amplification of rpob DNA is required 
to generate rifampicin susceptibility results;13 thus all 
14 trace positive results had indeterminate rifampicin 
resistance in our study. Culture­based drug susceptibility 
testing was not done. MGIT culture reported contaminated 
results in 13 (9%) of 142 cultures performed.
When analysing by MRC grade, the sensitivity of Xpert 
Ultra against the composite microbiological reference 
standard was 100% in grade 1 disease, 96% in grade 2 
disease, and 82% in grade 3 disease. Using the uniform 
case definition, the sensitivity of Xpert Ultra was 100% in 
grade 1 disease, 74% in grade 2 disease, and 69% in grade 3 
disease. The observation of decreasing sensitivity with 
advancing disease MRC severity grade held true for Xpert 
and MGIT (appendix p 9).
The CSF from 45 participants with confirmed crypto­
coccal meningitis and no clinical suspicion of tuber­
culosis coinfection were all negative on Xpert Ultra, 
suggesting false positivity (eg, laboratory contamination) 
is a rare occurrence (specificity 100%, 95% CI 92–100).
Univariate analysis found that Glasgow Coma Scale 
score of less than 15, CSF pleocytosis, and lower CSF 
glucose, higher CSF protein, and higher CSF lactate 
concentrations were all positively associated with 
micro biological confirmation of tuber culous meningitis 
(table 3). Log2 CSF lactate con centration was not included 
in the multivariate analysis because of the large amount 
of missing data. In the multivariable logistic regression 
model, lower log2 CSF glucose concentration remained 
positively asso ciated with microbiological confirmation 
of tuberculous menin gitis, although the multivariable 
model analysis was restricted to 101 participants with a 
complete dataset for the variables included in the model 
(table 3). The median volume of CSF spun down for 
tuberculosis testing was 8 mL (IQR 5–11) and each 
doubling (ie, log2 increase) of CSF volume spun down 
increased the odds of tuberculosis confirmation by 
40%, although this did not achieve statistical significance 
(table 3).
Of the nine participants who were positive only by 
Xpert Ultra, six had started antiretroviral therapy 
within the 6 weeks preceding the study (median 
duration 28 days, IQR 17–35), a timing consistent with 
unmasking immune reconstitution inflammatory 
syndrome.
Discussion
In this HIV­positive population with suspected menin gitis, 
Xpert Ultra showed higher sensitivity to detect tuberculous 
meningitis than either Xpert or MGIT culture against both 
considered reference standards, although the difference 
was not significant when Xpert Ultra was compared with 
MGIT culture against the composite microbiological 
reference standard. These findings from fresh CSF corro­
borate our earlier findings from cryopreserved CSF, 
supporting the robustness of these data.8
Importantly, more than a third (14 [36%] of 39) of 
positive Xpert Ultra results were in the trace category 
Univariate model Multivariable model
n Odds ratio (95% CI) p value n Adjusted odds ratio (95% CI) p value
Age, per year 204 0·98 (0·95–1·01) 0·26 ·· ·· ··
Male sex 204 1·14 (0·58–2·26) 0·70 ·· ·· ··
Duration of headache, per day 168 1·00 (0·98–1·01) 0·95 ·· ·· ··
Glasgow Coma Scale score
15* 72 1 (ref) ·· 35 1 (ref) ··
11–14 97 3·62 (1·39–9·39) 0·0083 46 3·71 (0·84–16·48) 0·084
≤10 33 5·50 (1·82–16·62) 0·0025 21 4·71 (0·93–23·82) 0·061
Log2 CD4 count, cells per µL 63 0·94 (0·71–1·34) 0·66 ·· ·· ··
On antiretroviral therapy 202 1·34 (0·67–2·66) 0·40 ·· ·· ··
Log2 CSF volume, mL 198 1·20 (0·84–1·72) 0·32 ·· ·· ··
Log2 CSF volume spun down, mL 96 1·40 (0·84–2·35) 0·20 ·· ·· ··
CSF pleocytosis† 189 4·94 (2·28–10·72) <0·0001 101 2·04 (0·33–12·74) 0·44
Log2 CSF glucose, mmol/L 122 0·31 (0·18–0·54) <0·0001 101 0·33 (0·17–0·65) 0·0010
Log2 CSF lactate, mmol/L‡ 88 5·76 (2·45–13·52) <0·0001 ·· ·· ··
Log2 CSF protein, mg/dL 166 2·10 (1·52–2·89) <0·0001 101 1·02 (0·56–1·87) 0·25
Variables that were significant (p<0·1) in the univariate model were included in the multivariable model. Odds ratios for log-transformed variables are per log2 increase. 
CSF=cerebrospinal fluid. *p=0·0001 with the likelihood ratio test. †>5 lymphocytes per µL of CSF. ‡CSF lactate was excluded from the multivariable model because of the 
amount of missing data.
Table 3: Univariate and multivariable analyses of factors potentially associated with microbiological confirmation of tuberculous meningitis
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(correlating to <100 CFUs per mL), which is usually 
below the limit of detection of Xpert and potentially 
below the limit of detection of tuberculosis culture. Of 
these 14 trace positive samples, only four were positive 
by Xpert and six by culture. The ability to detect non­
viable organisms is another reason why detection of 
tuberculosis might be improved with molecular tests 
versus culture.
As part of the uniform case definition, we did not 
include participants with possible tuberculous meningitis 
(n=74) in our analysis because of the non­specific nature 
of this category in this study population with advanced 
HIV—eg, due to concurrent neurological pathology such 
as PML (study population median CD4 T cell count 
46 cells/μL, IQR 11–130).
With increasing market penetration of the Xpert plat­
form in countries with high tuberculosis burden24 and a 
turnaround time of 84 min, Xpert Ultra is the best point­
of­care test for tuberculous meningitis currently available 
and has been endorsed by WHO as the best initial test for 
tuberculous meningitis.25 Yet, our study shows a moderate 
76·5% sensitivity of Xpert Ultra against a uniform case 
definition of probable or definite tuberculous meningitis, 
giving a negative predictive value of 92·7%. In other 
words, nearly a fifth of patients (nine [18%] of 51) with 
clinical phenotypes and CSF profiles highly suggestive of 
tuberculous meningitis and negative for all other tested 
pathogens were negative by Xpert Ultra (and by Xpert and 
culture). Four of these participants died from their illness, 
one with macroscopic post­mortem findings compatible 
with tuberculous menin gitis. Our belief is that a pro­
portion of these are false­negative results, but this remains 
to be determined in future studies. CSF could also be 
tested with Xpert Ultra on multiple days if safe to do so 
and a false­negative result is suspected; we have employed 
this strategy with success in several patients (outside of 
this study). Markers of host response should also be 
considered as potential future adjunctive diagnostic tests, 
although to date, none have been successful.26 Currently, 
clinical judgment remains relevant when making treat­
ment decisions regarding tuberculous meningitis.11
Multivariable analysis showed low CSF glucose to be 
associated with microbiologically confirmed tuberculous 
meningitis. CSF lactate could not be taken through to the 
multivariable model because of the amount of missing 
data but was found to be strongly associated with 
microbiologically confirmed tuberculous menin gitis in 
the univariate model and thus warrants further investi­
gation as a diagnostic marker. Handheld glucometers and 
lactate meters are true point­of­care tests, with results 
available at the bedside within a matter of seconds. A low 
CSF glucose concen tration (<2·2 mmol/L, <40 mg/dL, or 
CSF to plasma glucose ratio <50%) in a patient with 
symptoms and signs suggestive of tuber culous meningitis, 
once bacterial menin gitis and cryptococcus have been 
excluded, is a good indication to consider antituberculous 
therapy regardless of tuberculosis­specific test results. 
The potential for using CSF glucose and lactate as com­
ponents of a comprehensive diagnostic algorithm focused 
on probability of diagnosis should be explored in future 
studies.
We believe that using Xpert Ultra on CSF samples is 
highly specific for the diagnosis of tuberculous menin­
gitis, although the absence of a perfect reference standard 
makes this difficult to prove. Furthermore, the inclusion 
of Xpert Ultra in the composite reference standard risked 
incorporation bias and is a limitation of this study. 
Yet, unlike sputum from the lungs, which can remain 
positive in the trace category on Xpert Ultra even years 
after treatment of prior pulmonary tuberculosis,27 CSF is 
a sterile body fluid that is replenished four to five times a 
day.28 Presence of M tuberculosis in the CSF progresses to 
death if untreated. In this study of hospitalised patients 
with advanced HIV who were from a tuberculosis­
endemic country and had symptoms of subacute 
meningitis, we feel that the probability of a false­positive 
DNA­based test is negligible.
The median total volume of CSF spun down for 
tuberculosis testing was 8·0 mL; however, this volume 
was then divided into four, with a median volume of 
approximately 2·0 mL per diagnostic test. We used an 
algorithm for stepwise dropping of tests when the CSF 
volume collected was less than 6 mL so the minimal 
input CSF volume would always be at least 2·0 mL per 
diagnostic test to maximise the likelihood of obtaining an 
accurate result for the patient. Each doubling of CSF 
volume spun down increased the odds of tuberculosis 
confirmation by 40%, although this association was not 
significant. Xpert has been noted in some studies to have 
improved performance when higher CSF volumes are 
used; this study cannot inform whether the same is true 
for Xpert Ultra.5,6 The stepwise use of tests on low­volume 
samples resulted in small samples receiving fewer tests 
and thus imperfect matching, with CSF from 204 patients 
tested with Xpert Ultra compared with only 166 with 
Xpert. There were also the common problems of culture, 
beyond diagnostic delay; only 142 culture results were 
received (including 13 that were contaminated) because 
of a number being lost when sent to an external 
mycobacterial laboratory.
11 (26%) of 42 patients with microbiologically con­
firmed tuberculous meningitis had an acellular CSF 
(fewer than five white blood cells per µL). All those with 
acellular CSF also had CSF opening pressure and total 
protein within the normal range and lower median CSF 
lactate concentrations (CSF lactate 4·6 mmo/mL vs 
9·5 mmol/mL in the definite tuberculous meningitis 
group). We previously reported that one in three patients 
with definite tuberculous meningitis have acellular 
CSF, a finding that has also been noted in other HIV­
positive cohorts outside of Asia.29 This observed 
absence of an inflammatory response in patients with 
microbiologically confirmed tuberculous meningitis 
could be explained by immune paresis secondary to 
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advanced HIV disease (CD4 count was available in two 
of 11 patients and was three cells per µL and six cells 
per µL, respectively), or by early presentation (three of 
11 patients had MRC grade 1 disease). Mortality was 
high in this subgroup despite the apparent absence of 
CSF inflammation, with six (55%) patients dying in 
hospital. Low CSF white blood cell count has been 
associated with death in a multivariate prognostic model 
in Vietnamese adults with tuberculous meningitis, and 
it is becoming increasingly clear that both absence 
of inflammation, as well as excessive inflammation, are 
deleterious in tuberculous meningitis.2,30
The sensitivity of all assays was highest in early disease 
(MRC grade 1), and sensitivity decreased as disease 
severity progressed. Although the numbers are small and 
the analysis of sensitivity by MRC grade was post hoc, 
this finding supports the notion that an increasing 
immune response (ie, inflammation) aimed at controlling 
bacillary load is the mediator of disease. Thereby, an 
inverse relationship might actually exist between CSF 
bacillary load and disease severity in this population. This 
hypo thesis warrants further investigation in immunology 
studies and highlights the importance of finding 
the optimal host­directed therapy to control damaging 
inflammation in this population.
When translating these results to the field, it is important 
to consider that in many hospital laboratory settings, 
centrifuging the CSF might not be feasible, in which case 
we would advise loading 2 mL of CSF directly into the 
Xpert Ultra cartridge to maximise the bacillary load, as 
dilution with sample reagent is not required for 
CSF. Additionally, although our cohort cannot inform 
diagnostic performance in an HIV­negative population, 
our paired analysis of specimens shows that Xpert 
Ultra performs better than Xpert in an HIV­positive 
population. Whether Xpert Ultra can improve outcomes 
of tuberculous meningitis or lessen unnecessary exposure 
to tuberculous meningitis medications remain to be 
determined. In this prospective study, with real­time Xpert 
Ultra results available to the clinical team within 24 h, in­
hospital mortality was 40% (17 of 42 patients) compared 
with 50% (11 of 22) in our previous study on cryopreserved 
CSF in which results were not available to guide 
management decisions.7,8 We cannot say whether this 
observed reduction in mortality is attributable to the 
availability of real­time Xpert Ultra results because this 
study was not designed to study the effect of Xpert Ultra 
on clinical outcomes. Additionally, this study included 
two clinical sites (Mulago and Mbarara hospitals), whereas 
the previous study was done solely in Mbarara hospital. 
Furthermore, given the time between this study and 
the previous study, additional potential confounding 
factors might be present that contribute towards the 
mortality difference. In addition to access to improved 
point­of­care diagnostics, earlier presentation to hospital, 
better supportive care, and optimised antimicrobial and 
anti­inflammatory treatments are required to reduce the 
high case­fatality in this population. Larger structural 
factors, such as poverty and weak health systems, also 
continue to play a role in the high mortality of tuberculosis 
and HIV coinfection and need to be addressed. At present, 
regular use of empirical therapy continues to be required 
for tuberculous meningitis.
In conclusion, Xpert Ultra offers a substantial improve­
ment in rapid and accurate diagnosis of tuberculous 
meningitis, and is superior to Xpert. However, Xpert Ultra 
does not represent a perfect rule­out test. Clinical judgment 
and empirical therapy remain important to improve 
outcomes for patients with tuberculous meningitis. In this 
exciting era of rapidly evolving molecular diagnostics and 
biomarkers, the development of a highly sensitive point­of­
care test that can facilitate rapid treatment and give 
clinicians confidence in rationalising the use of empirical 
tuberculosis treatment is a realistic goal.
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